These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 22362770

  • 1. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.
    Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W.
    J Biol Chem; 2012 Apr 20; 287(17):14012-22. PubMed ID: 22362770
    [Abstract] [Full Text] [Related]

  • 2. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
    Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.
    J Biol Chem; 2013 Jun 21; 288(25):18448-57. PubMed ID: 23661698
    [Abstract] [Full Text] [Related]

  • 3. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
    Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W.
    Oncogene; 2008 Dec 11; 27(58):7260-73. PubMed ID: 18794797
    [Abstract] [Full Text] [Related]

  • 4. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
    Wykosky J, Gibo DM, Debinski W.
    Mol Cancer Ther; 2007 Dec 11; 6(12 Pt 1):3208-18. PubMed ID: 18089715
    [Abstract] [Full Text] [Related]

  • 5. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
    Tognolini M, Incerti M, Hassan-Mohamed I, Giorgio C, Russo S, Bruni R, Lelli B, Bracci L, Noberini R, Pasquale EB, Barocelli E, Vicini P, Mor M, Lodola A.
    ChemMedChem; 2012 Jun 11; 7(6):1071-83. PubMed ID: 22529030
    [Abstract] [Full Text] [Related]

  • 6. Receptor-binding domain of ephrin-A1: production in bacterial expression system and activity.
    Nekrasova OV, Sharonov GV, Tikhonov RV, Kolosov PM, Astapova MV, Yakimov SA, Tagvey AI, Korchagina AA, Bocharova OV, Wulfson AN, Feofanov AV, Kirpichnikov MP.
    Biochemistry (Mosc); 2012 Dec 11; 77(12):1387-94. PubMed ID: 23244735
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design and evaluation of EphrinA1 mutants with cerebral protective effect.
    Zhu Y, Gao Y, Zheng D, Shui M, Yu K, Liu X, Lin Y, Su L, Yang W, Wang Y.
    Sci Rep; 2017 May 15; 7(1):1881. PubMed ID: 28507312
    [Abstract] [Full Text] [Related]

  • 9. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
    Salaita K, Nair PM, Petit RS, Neve RM, Das D, Gray JW, Groves JT.
    Science; 2010 Mar 12; 327(5971):1380-5. PubMed ID: 20223987
    [Abstract] [Full Text] [Related]

  • 10. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
    Wykosky J, Gibo DM, Stanton C, Debinski W.
    Mol Cancer Res; 2005 Oct 12; 3(10):541-51. PubMed ID: 16254188
    [Abstract] [Full Text] [Related]

  • 11. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
    Pala D, Castelli R, Incerti M, Russo S, Tognolini M, Giorgio C, Hassan-Mohamed I, Zanotti I, Vacondio F, Rivara S, Mor M, Lodola A.
    J Chem Inf Model; 2014 Oct 27; 54(10):2621-6. PubMed ID: 25289483
    [Abstract] [Full Text] [Related]

  • 12. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
    Tandon M, Vemula SV, Sharma A, Ahi YS, Mittal S, Bangari DS, Mittal SK.
    J Gene Med; 2012 Feb 27; 14(2):77-89. PubMed ID: 22228563
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size.
    Zapata-Mercado E, Biener G, McKenzie DM, Wimley WC, Pasquale EB, Raicu V, Hristova K.
    J Biol Chem; 2022 Oct 27; 298(10):102370. PubMed ID: 35970390
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
    Gomez-Soler M, Petersen Gehring M, Lechtenberg BC, Zapata-Mercado E, Hristova K, Pasquale EB.
    J Biol Chem; 2019 May 31; 294(22):8791-8805. PubMed ID: 31015204
    [Abstract] [Full Text] [Related]

  • 17. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
    Xu Q, Lin WC, Petit RS, Groves JT.
    Biophys J; 2011 Dec 07; 101(11):2731-9. PubMed ID: 22261062
    [Abstract] [Full Text] [Related]

  • 18. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
    Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK.
    Cancer Gene Ther; 2004 Nov 07; 11(11):757-66. PubMed ID: 15359289
    [Abstract] [Full Text] [Related]

  • 19. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.
    Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W.
    Mol Cell Biol; 2012 Aug 07; 32(16):3253-64. PubMed ID: 22688511
    [Abstract] [Full Text] [Related]

  • 20. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
    Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, Rajashankar KR, Wang B, Nikolov DB.
    EMBO Rep; 2009 Jul 07; 10(7):722-8. PubMed ID: 19525919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.